This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neuwelt, E. A. Articles by Muldoon, L. L. Search for Related Content PubMed PubMed Citation Articles by Neuwelt, E. A. Articles by Muldoon, L. L.

Therapeutic Efficacy of Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model¹

Department of Neurology [E. A. N., L. L. M.], Department of Neurosurgery [E. A. N.], Division of Hematology [T. G. D.], and Department of Cell and Developmental Biology [L. L. M.], Oregon Health Sciences University, Portland, Oregon 97201, and Veterans Administration Medical Center, Portland, Oregon 97201 [E. A. N., M. A. P., B. P. H.]

Modulation of thiol levels may alter both the efficacy and toxicity of chemotherapeutic agents. We investigated cytoenhancement, using L-buthionine-[S,R]-sulfoximine (BSO) to reduce cellular glutathione levels prior to intracarotid alkylator administration. We also evaluated chemoprotection against chemotherapy-induced systemic toxicity when the thiol agents N-acetylcysteine (NAC) and sodium thiosulfate were administered into the descending aorta to limit brain delivery. BSO treatment reduced rat brain and intracerebral tumor glutathione levels by 50–65%, equivalent to the reduction in liver and s.c. tumor. BSO treatment significantly enhanced the toxicity of chemotherapy with carboplatin, melphalan, and etoposide phosphate against granulocytes, total white cells, and platelets. Intracarotid administration of NAC resulted in high delivery to the brain, whereas infusion via the descending aorta minimized brain delivery. When NAC, with or without sodium thiosulfate, was administered via aortic infusion prior to chemotherapy, the magnitude of the bone marrow toxicity nadir was minimized, even with BSO-enhanced myelosuppression. Thus, BSO depleted brain and brain tumor glutathione but thereby increased chemotherapy-induced myelosuppression. Surprisingly, although NAC was found to readily cross the blood-brain barrier when given into the carotid artery, aortic infusion of NAC resulted in minimal exposure to the central nervous system (CNS) vasculature because of rapid clearance. As a result, aortic infusion of NAC to perfuse bone marrow and minimize myelosuppression and toxicity to visceral organs could be performed without interfering with the CNS cytotoxicity of intracarotid alkylators, even after BSO depletion of CNS glutathione.

This article has been cited by other articles:

				A. Singh, S. Boldin-Adamsky, R. K. Thimmulappa, S. K. Rath, H. Ashush, J. Coulter, A. Blackford, S. N. Goodman, F. Bunz, W. H. Watson, et al. RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy Cancer Res., October 1, 2008; 68(19): 7975 - 7984. [Abstract] [Full Text] [PDF]

				J. Alexandre, C. Nicco, C. Chereau, A. Laurent, B. Weill, F. Goldwasser, and F. Batteux Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst, February 15, 2006; 98(4): 236 - 244. [Abstract] [Full Text] [PDF]

				D. T. Dickey, Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1052 - 1058. [Abstract] [Full Text] [PDF]

				Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 424 - 431. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, et al. New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting Clin. Cancer Res., January 15, 2005; 11(2): 421 - 428. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, M. A. Pagel, D. F. Kraemer, D. R. Peterson, and L. L. Muldoon Bone Marrow Chemoprotection without Compromise of Chemotherapy Efficacy in a Rat Brain Tumor Model J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 594 - 599. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, N. Ferrari, W. A. Hall, E. R. Laws, R. E. McLendon, L. L. Muldoon, D. Peereboom, D. R. Peterson, C. P. Reynolds, et al. Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium Clin. Cancer Res., June 1, 2002; 8(6): 1702 - 1709. [Abstract] [Full Text] [PDF]